Abstract
Cancer stem cells (CSCs), also known as tumor-initiating cells, have been identified in several human malignancies, including human malignant melanoma. The frequency of malignant melanoma-initiating cells (MMICs), which are identified by their expression of ATP-binding cassette (ABC) family member ABCB5, correlates with disease progression in human patients. Furthermore, targeted MMIC ablation through ABCB5 inhibits tumor initiation and growth in preclinical xenotransplantation models, pointing to potential therapeutic promise of the CSC concept. Recent advances also show that CSCs can exert pro-angiogenic roles in tumor growth and serve immunomodulatory functions related to the evasion of host anti-tumor immunity. Thus, MMICs might initiate and sustain tumorigenic growth not only as a result of CSC-intrinsic self-renewal, differentiation and proliferative capacity, but also based on pro-tumorigenic interactions with the host environment.
Keywords: Cancer stem cells, Melanoma, Malignant melanoma-initiating cells, Melanoma stem cells, ABCB5, Angiogenesis, Immunity
Anti-Cancer Agents in Medicinal Chemistry
Title: Tumor Initiation in Human Malignant Melanoma and Potential Cancer Therapies
Volume: 10 Issue: 2
Author(s): Jie Ma and Markus H. Frank
Affiliation:
Keywords: Cancer stem cells, Melanoma, Malignant melanoma-initiating cells, Melanoma stem cells, ABCB5, Angiogenesis, Immunity
Abstract: Cancer stem cells (CSCs), also known as tumor-initiating cells, have been identified in several human malignancies, including human malignant melanoma. The frequency of malignant melanoma-initiating cells (MMICs), which are identified by their expression of ATP-binding cassette (ABC) family member ABCB5, correlates with disease progression in human patients. Furthermore, targeted MMIC ablation through ABCB5 inhibits tumor initiation and growth in preclinical xenotransplantation models, pointing to potential therapeutic promise of the CSC concept. Recent advances also show that CSCs can exert pro-angiogenic roles in tumor growth and serve immunomodulatory functions related to the evasion of host anti-tumor immunity. Thus, MMICs might initiate and sustain tumorigenic growth not only as a result of CSC-intrinsic self-renewal, differentiation and proliferative capacity, but also based on pro-tumorigenic interactions with the host environment.
Export Options
About this article
Cite this article as:
Ma Jie and Frank H. Markus, Tumor Initiation in Human Malignant Melanoma and Potential Cancer Therapies, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (2) . https://dx.doi.org/10.2174/187152010790909254
DOI https://dx.doi.org/10.2174/187152010790909254 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential Cancer Gene Therapy by Baculoviral Transduction
Current Gene Therapy Emerging Family of Protein-protein Interaction Inhibitors Targeting PD-1 Checkpoint Pathway
Current Cancer Therapy Reviews Tamarind Inhibits Solar-Simulated Ultraviolet Radiation-Induced Suppression of Recall Responses in Humans
Letters in Drug Design & Discovery Receptor Tyrosine Kinases: The Main Targets for New Anticancer Therapy
Current Drug Targets Nanoparticle Based Delivery of Protease Inhibitors to Cancer Cells
Current Medicinal Chemistry Breast Cancer: Understanding Sensitivity and Resistance to Chemotherapy and Targeted Therapies to Aid in Personalised Medicine
Current Cancer Drug Targets The Emerging Role of Aromatase Inhibitors in the Adjuvant Management of Breast Cancer
Reviews on Recent Clinical Trials RNA Interference-Based Therapeutics: New Strategies to Fight Infectious Disease
Infectious Disorders - Drug Targets Dedication of the Third Issue of ‘Current Alzheimer Research’ to President Ronald Reagan (1911-2004)
Current Alzheimer Research Relevance of Micrometastases and Targeting the Bone Marrow Niche with Zoledronic Acid in Breast Cancer
Current Cancer Therapy Reviews Asymmetric Vinylogous Mukaiyama Aldol Reactions Using Vinylketene N,O-Acetals in Total Syntheses of Natural Products
Mini-Reviews in Organic Chemistry Nitrogen-Containing Heterocycles as Anticancer Agents: An Overview
Anti-Cancer Agents in Medicinal Chemistry Cyclic Peptide Containing Hydrophobic and Positively Charged Residues as a Drug Delivery System for Curcumin
Current Drug Delivery Nanostructured Therapeutic Systems of PUFAs for the Treatment of Glioblastoma Multiforme
Current Drug Metabolism An Emerging Therapeutic Approach by Targeting Myoferlin (MYOF) for Malignant Tumors
Current Topics in Medicinal Chemistry Antileishmanial Patents Antileishmanial Current Drugs and Relevant Patents
Recent Patents on Anti-Infective Drug Discovery Chronobiology of the Neuroimmunoendocrine System and Aging
Current Pharmaceutical Design Microfluidic approaches to synchrotron radiation-based Fourier transform infrared (SR-FTIR) spectral microscopy of living biosystems
Protein & Peptide Letters Design of Novel Antitumor DNA Alkylating Agents: The Benzacronycine Series
Current Medicinal Chemistry - Anti-Cancer Agents Antiangiogenic Therapy
Current Pharmaceutical Design